Cookies are a small piece of text created by websites and stored on your computer. They play an important role in the experience and functionality of a website. They can help make a website easier to use, gather statistics, enable transactions, provide security, and much more.
There are three basic types of cookies:
The following describes the cookies we use:
|This stores your preference for enabling or disabling non‐essential cookies.|
|Gathering website statistics using Google Analytics||
Google Analytics cookies gather information on the number of visits, pages viewed, the duration of time spent on pages, and other site statistics.
You can disable all Google Analytics on your web browser using the Google Analytics Opt‐Out Browser Add‐on.
|System||ASP.NET_SessionId||This cookie is used by the system to maintain a connection to the website while you browse its content.|
|Visitor Segmentation||visittrack||Used to customize the appearance of the site depending on the type of user.|
|Cookie Notification||cookie_notification||Used to suppress display of cookie notification when the notification has been dismissed.|
|Display Retargeting Pixel||
|A display retargeting pixel is code that you place on your website. It helps you gather information from third-party service provider display ads, optimize ads based on collected data, build targeted audiences for future ads, and remarket to qualified leads-people who have already taken some kind of action on your website.|
|Marketing cookies to track traffic from source to webinar sign up link.|
You can disable non‐essential cookies on our website. This will also delete existing cookies.
Note that Cookie Banner, Cookie Preferences, and other essential system cookies shall remain.
Important Safety Information
WARNING: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS
Patients being treated with Vitamin K antagonist therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the risk of thromboembolic events, especially in patients with history of such events. Resumption of anticoagulation therapy should be carefully considered once the risk of thromboembolic events outweighs the risk of acute bleeding. Both fatal and nonfatal arterial and venous thromboembolic complications have been reported in clinical trials and postmarketing surveillance. Monitor patients receiving Kcentra, and inform them of signs and symptoms of thromboembolic events. Kcentra was not studied in subjects who had a thromboembolic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within the prior 3 months. Kcentra might not be suitable for patients with thromboembolic events in the prior 3 months.
Kcentra is contraindicated in patients with known anaphylactic or severe systemic reactions to Kcentra or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). Kcentra is also contraindicated in patients with disseminated intravascular coagulation. Because Kcentra contains heparin, it is contraindicated in patients with heparin-induced thrombocytopenia (HIT).
Hypersensitivity reactions to Kcentra may occur. If patient experiences severe allergic or anaphylactic type reactions, discontinue administration and institute appropriate treatment.
In clinical trials, the most frequent (≥2.8%) adverse reactions observed in subjects receiving Kcentra were headache, nausea/vomiting, hypotension, and anemia. The most serious adverse reactions were thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.
Kcentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA—eg, warfarin) therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure. Kcentra is for intravenous use only.
Please see full prescribing information for Kcentra.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You are now leaving the current website.
The site you are accessing is maintained by a third party over whom CSL Behring has no control. CSL Behring does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site. CSL Behring is not responsible for third-party content or the consequences of your use thereof.
Do you want to continue?